Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06263543 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06263543 · ClinicalTrials.gov record · last posted 2026-08-12

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Study acronym: SERIES
StatusRecruiting
PhasePhase 2
Started2024-06-17
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd.

Protocol amendment history 2 changes detected by DataLookout

2026-08-13
Primary completion pushed: 2026-06 → 2028-06
2026-08-13
Completion pushed: 2026-12 → 2028-12
Trial Details
NCT Number NCT06263543
Lead Sponsor Reshma L. Mahtani, D.O.
Collaborators: Gilead Sciences
Conditions Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
Enrollment 75 participants
Start Date 2024-06-17
Primary Completion 2028-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-12